media – Page 609 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Breakthrough-Scientists reverse aging in human cells

New research published in the journal BMC Cell Biology shows that old human cells can be rejuvenated using chemicals similar to resveratrol, which is a substance found in red wine and dark chocolate.
- Source: medicalnewstoday
- 623
- November 9, 2017
cell Researches resveratrol
Mobile Digital health has the potential to save $46 billion a year in health spending

Existing digital health products hold the potential to save the nation $46 billion in healthcare spending if they’re deployed comprehensively, according to a new report from IQVIA, which on Tuesday renamed itself from Quintiles/IMS Health.
- Source: healthcareitnews
- 591
- November 9, 2017
asthma cardiac diabetes healthcare Market Views
FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN

Cellectis (Alternext: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold, previously announced on September 4, 2017, on Phase 1 trials of Cellectis’ UCART123 product candidate in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- Source: Cellectis
- 565
- November 9, 2017
Cellectis Clinical Trials FDA immunotherapies UCART
7 Physical Symptoms of Depression

There is increasing evidence that the same mechanisms that cause depression in the brain can also affect other body systems as well. Here are seven physical symptoms that can be found alongside depression.
- Source: blogs.psychcentral
- 596
- November 9, 2017
bipolar depression Researches
Sanofi Taps into Berg’s AI Platform for Developing Better Flu Vaccine

Machine learning technologies have already made huge strides in supporting the efforts of pharmaceutical companies in developing personalized medicines and novel biomarkers. This has been found to be helpful, notably for understanding the efficacy of prophylactic vaccines used for combating infectious diseases.
- Source: researchmoz.us
- 640
- November 8, 2017
Artificial Intelligence Market Views vaccine
EU OKs low-dose Xarelto to prevent recurrent VTE

A lower dose formulation of Bayer and Janssen’s bloodthinner Xarelto has been approved by European regulators for preventing recurrent venous thromboembolism, expanding treatment options for patients.
- Source: Pharmatimes
- 622
- November 8, 2017
cardiovascular New Approvals venous thromboembolism VTE
Cancer cells destroyed in just 3 days with new technique

Cancer cells are relentless, possessing the vexatious ability to develop resistance to current therapies and making the disease hugely challenging to treat. However, an exciting new study may have identified cancer's weak spot; the discovery has already led to the near-eradication of the disease in cell cultures.
- Source: medicalnewstoday
- 677
- November 8, 2017
cancer cell chromatin Researches
Low vitamin D may raise risk of kidney failure

New research, conducted by scientists at the Johns Hopkins University School of Medicine in Baltimore, MD, finds that low vitamin D raises the risk of organ damage and renal disease in people with lupus – an autoimmune disease.
- Source: medicalnewstoday
- 1,061
- November 8, 2017
autoimmune inflammation lupus Researches SLE vitamin
Black Death and incurable Marburg Virus now spreading across Africa’s cities

Africa is currently contending with two serious disease outbreaks. The pneumonic plague has been making headlines as it sweeps across Madagascar, but there are concerns about it are being eclipsed by a far more sinister threat: A rare and fatal virus known Marburg virus disease (MVD), which has now broken out in Uganda.
- Source: naturalnews
- 1,129
- November 8, 2017
Market Views MVD pneumonic plague WHO
FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer

The U.S. Food and Drug Administration(FDA) has expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.
- Source: Worldpharmanews
- 443
- November 8, 2017
BRAF V600 ECD FDA Zelboraf (vemurafenib)

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.